Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
|
| gptkbp:activeIngredient |
gptkb:oritavancin
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
J01XA04
|
| gptkbp:CASNumber |
171099-57-3
|
| gptkbp:chemicalFormula |
C86H97Cl3N10O26
|
| gptkbp:contraindication |
hypersensitivity to oritavancin
|
| gptkbp:halfLife |
~245 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orbactiv
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:The_Medicines_Company
|
| gptkbp:mechanismOfAction |
inhibits cell wall synthesis
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache |
| gptkbp:spectrumOfActivity |
Gram-positive bacteria
|
| gptkbp:usedFor |
acute bacterial skin and skin structure infections
|
| gptkbp:bfsParent |
gptkb:oritavancin
|
| gptkbp:bfsLayer |
6
|